(Q53381227)

13 May 2018

title

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. (English)

1 reference

13 May 2018

non-small-cell lung carcinoma

main subject

patient

0 references

1 reference

7

J C Soria

1 reference

13 May 2018

Fabrice André

3

object named as

F André

1 reference

13 May 2018

Nathalie Auger

5

object named as

N Auger

1 reference

13 May 2018

author name string

D Planchard

1

1 reference

13 May 2018

Y Loriot

2

1 reference

13 May 2018

A Gobert

4

1 reference

13 May 2018

L Lacroix

6

1 reference

13 May 2018

publication date

12 August 2015

1 reference

13 May 2018

published in

Annals of Oncology

1 reference

13 May 2018

volume

26

1 reference

13 May 2018

issue

10

1 reference

13 May 2018

page(s)

2073-2078

1 reference

13 May 2018

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV319

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV319

1 reference

13 May 2018

1 reference

13 May 2018